Can veterinary ivermectin formulations legally be prescribed or given to humans and what are FDA guidelines?

Checked on February 6, 2026
Disclaimer: Factually can make mistakes. Please verify important information or breaking news. Learn more.

Executive summary

Veterinary ivermectin formulations are not approved for use in humans and the U.S. Food and Drug Administration (FDA) warns people not to take animal ivermectin to prevent or treat COVID-19 or any other human condition [1] [2]. Human ivermectin exists as specific FDA‑approved oral tablets and prescription topical products for certain parasitic and dermatologic conditions, but animal products are formulated, concentrated, labeled, and regulated for animals and carry safety and toxicity risks if used in people [3] [4] [5].

1. Legal status and FDA guidance: animal ivermectin is not for humans

The FDA’s explicit regulatory message is that ivermectin products intended for animals should not be used in humans and that veterinary formulations “should only be given to animals for approved uses or as prescribed by a veterinarian” under veterinary extra‑label rules — they are not approved for human treatment, including for COVID‑19 [1] [2]. The FDA has repeatedly stated it has not authorized or approved ivermectin for prevention or treatment of COVID‑19 in humans, and urges reporting of anyone claiming an animal product prevents or cures COVID‑19 [6] [2].

2. What can be prescribed to humans: approved human ivermectin and off‑label use

For humans the FDA-approved ivermectin products are specific oral tablets for certain parasitic infections and prescription topical formulations for conditions such as head lice and rosacea; those human formulations are approved at defined doses and routes of administration [3] [6]. The FDA also notes that, in general, health care professionals may legally prescribe an FDA‑approved human drug for an unapproved (off‑label) use when they judge it medically appropriate for an individual patient, but that flexibility applies to approved human drugs, not to using veterinary products in people [6].

3. Safety, toxicity and real‑world harms tied to animal formulations

Animal ivermectin products are often far more concentrated and delivered by routes not used in human practice (e.g., injectable or pour‑ons for livestock), which raises risk of overdose and severe adverse events; regulators and medical societies cite increased poison‑control calls, hospitalizations, and documented neurotoxicity after people used veterinary formulations or nonstandard routes [5] [7] [8] [9]. A case report described intravenous veterinary ivermectin given to a patient that produced neurotoxicity and doses far above human-approved regimens, underscoring the mismatch in formulation and dosing between veterinary and human products [9].

4. Claims of antiviral activity vs. clinical evidence and agency evaluation

Interest in ivermectin for COVID‑19 grew after an in vitro study showed inhibition of SARS‑CoV‑2, but the FDA and independent treatment panels emphasize that those laboratory findings do not translate to proven clinical benefit; the NIH COVID‑19 Treatment Guidelines Panel states there are insufficient data to recommend ivermectin for COVID‑19, and the FDA has said available clinical trial data do not demonstrate efficacy for COVID‑19 [10] [11] [6]. Multiple public health bodies therefore warn against self‑medication with animal products and against relying on veterinary formulations as substitutes for approved human therapies [2] [12].

5. Practical implications and the narrow legal conclusion

The narrow legal and regulatory conclusion from available agency guidance is unambiguous: veterinary ivermectin products are not approved for human use and should not be given to people, and the FDA actively warns against such use and asks the public to report fraudulent claims [1] [2]. While physicians can use approved human drugs off‑label in clinical practice, the guidance and documented safety incidents make clear that substituting an animal formulation for an approved human product is outside the FDA’s endorsement and entails significant safety and legal risks that clinicians and the public should not assume are permissible or safe [6] [7].

Want to dive deeper?
What are the FDA rules for extra‑label drug use in veterinary medicine and how do they differ from human off‑label prescribing?
What clinical trials and systematic reviews have evaluated ivermectin for COVID‑19 and what are their main findings?
How have poison control center reports and hospitalizations changed during periods of increased public use of veterinary ivermectin?